- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07919834
Ultrasonographic Tissue Thickness After Complex Decongestive Therapy in Lower-Limb Lymphedema
Effect of Complex Decongestive Therapy on Subcutaneous Tissue Thickness in Lower-Limb Lymphedema: A Prospective Ultrasonographic Study With Contralateral Internal Control
This prospective single-center study evaluated whether 4 weeks of phase-1 complex decongestive therapy (manual lymphatic drainage, multilayer short-stretch bandaging, decongestive exercise, and skin care) changes dermal and subcutaneous tissue thickness measured by high-frequency ultrasonography in adults with unilateral International Society of Lymphology stage 1-2 lower-limb lymphedema. Measurements were made at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control and body weight was recorded to distinguish local tissue change from systemic weight change.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
Participants received a standardized 20-session (5 days/week, 4 weeks) intensive-phase complex decongestive therapy program delivered by an experienced physiotherapist. Ultrasonographic measurements were performed with a 10-14 MHz linear probe using a minimal-compression technique after 15 minutes of supine rest, at the same time of day, by an assessor blinded to baseline values; intra-rater reliability (intraclass correlation coefficient 0.92) was established in 10 patients. The sample size (n = 34; Cohen's d = 0.5, power 80%, alpha 0.05; 40 recruited) was calculated with G*Power. Paired comparisons (paired t-test or Wilcoxon signed-rank test), 95% confidence intervals, Cohen's d, and Pearson correlation of treatment response with age, body mass index, and disease duration were planned.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Kayseri, Turkiet (Türkiye), 38080
- Kayseri City Training and Research Hospital
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Adults presenting to the Physical Medicine and Rehabilitation outpatient clinic of Kayseri City Hospital with unilateral lower-limb lymphedema and an indication for intensive-phase complex decongestive therapy.
Beskrivning
Inclusion Criteria:
- Age 18 years or older
- Unilateral lower-limb lymphedema, International Society of Lymphology stage 1 or 2 (2020 consensus)
- Diagnosis supported by lymphoscintigraphy
- Indication for intensive-phase complex decongestive therapy
- No previous full course of complex decongestive therapy on the affected limb
- Written informed consent
Exclusion Criteria:
- Active cellulitis or erysipelas at the measurement sites
- Active, recurrent, or metastatic malignancy
- Decompensated heart failure or history of deep vein thrombosis
- Bilateral lymphedema
- Cognitive impairment preventing adherence to treatment
Studieplan
Hur är studien utformad?
Designdetaljer
- Observationsmodeller: COHORT
- Tidsperspektiv: PROSPECTIVE
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
Lower-limb lymphedema, complex decongestive therapy
Adults with unilateral ISL stage 1-2 lower-limb lymphedema who received 4 weeks (20 sessions) of phase-1 complex decongestive therapy as standard care. Dermal and subcutaneous tissue thickness were measured by high-frequency ultrasonography at suprapatellar and infrapatellar sites of both limbs before and after treatment; the unaffected limb served as an internal control. |
Phase-1 (intensive) complex decongestive therapy delivered 5 days per week for 4 weeks (20 sessions) by an experienced physiotherapist: Vodder-technique manual lymphatic drainage (30-45 min), multilayer short-stretch compression bandaging from the toes to the proximal thigh, decongestive range-of-motion exercise performed with bandages in place, and daily skin care with a pH 5.5 moisturizer.
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in subcutaneous tissue thickness of the affected limb at the suprapatellar site
Tidsram: Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)
|
Subcutaneous tissue thickness (dermis-subcutis interface to deep fascia) measured in millimeters by B-mode ultrasonography with a 10-14 MHz linear probe using a minimal-compression technique. |
Baseline and end of week 4 (after 20 sessions of complex decongestive therapy)
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in subcutaneous tissue thickness of the affected limb at the infrapatellar site
Tidsram: Baseline and end of week 4
|
Subcutaneous tissue thickness in millimeters measured by B-mode ultrasonography (10-14 MHz linear probe, minimal-compression technique). |
Baseline and end of week 4
|
|
Change in dermal thickness of the affected limb at the suprapatellar and infrapatellar sites
Tidsram: Baseline and end of week 4
|
Dermal thickness (skin surface to dermis-subcutis interface) in millimeters measured by B-mode ultrasonography. |
Baseline and end of week 4
|
|
Change in subcutaneous tissue thickness of the unaffected (control) limb
Tidsram: Baseline and end of week 4
|
Subcutaneous tissue thickness of the contralateral unaffected limb at the suprapatellar and infrapatellar sites, in millimeters, measured by B-mode ultrasonography; serves as an internal control. |
Baseline and end of week 4
|
|
Change in body weight
Tidsram: Baseline and end of week 4
|
Body weight in kilograms measured on the same calibrated scale, recorded to distinguish local tissue change from systemic weight change. |
Baseline and end of week 4
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Correlation of subcutaneous thickness change with disease duration, age, and body mass index
Tidsram: Baseline and end of week 4
|
Pearson correlation coefficients between the change in suprapatellar subcutaneous thickness of the affected limb and disease duration (months), age (years), and body mass index (kg/m2). |
Baseline and end of week 4
|
Samarbetspartners och utredare
Sponsor
Utredare
- Huvudutredare: Abdullah Goktug Yazar, MD, Kayseri City Hospital
- Studiestol: Ayse Guc, MD, Kayseri City Hospital
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 2025-491
- 491 (Annan identifierare: Kayseri City Hospital Clinical Research Ethics Committee)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .